Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) said Sunday it has signed a definitive agreement to acquire ITM Isotope Technologies Munich SE, a privately held German company that makes the radioactive isotopes used in a growing class of cancer drugs called radiopharmaceuticals, or radioligand therapies. These drugs attach a radioactive isotope to a molecule that homes in on tumor cells, delivering radiation directly to cancer while sparing more of the surrounding healthy tissue. For Telix, an Australian company that already sells three FDA-approved cancer-imaging products, this deal is less about acquiring one new drug and more about controlling the isotope supply chain that its business, and its competitors’ businesses, run on.
What Telix Is Actually Buying
ITM, founded in 2004, says it is the world’s largest producer of non-carrier-added lutetium-177 (177Lu), the isotope used in both of Novartis’s approved radiopharmaceuticals, Lutathera and Pluvicto, as well as in several of Telix’s own pipeline candidates. That claim holds up under scrutiny: independent trade coverage dating back to 2023 has described ITM’s Munich-area facility as the world’s largest 177Lu production site, and ITM has separately been named as a long-term isotope supplier feeding Pluvicto’s commercial supply chain. ITM also produces actinium-225 and terbium-161, two isotopes drawing growing interest across the field, and holds a 15-year exclusive agreement for irradiation services at Bruce Power’s nuclear reactors in Canada.
The company reported 2025 revenue of $273 million, according to its own audited financial statements, with a 40% compound annual growth rate since 2021. It runs two GMP-certified manufacturing sites in Germany and distributes to 65 countries.
Deal Terms, Line by Line
Telix will pay $1.65 billion upfront for 100% of ITM’s shares, on a cash-free, debt-free basis. That breaks down as roughly $1.25 billion in newly issued Telix shares (105.8 million shares, priced at $11.84 each based on a 30-day trailing volume-weighted average price), $302 million of ITM net debt assumed by Telix, and $96 million in management equity rollover and transaction costs. Those three figures add up to the disclosed $1.65 billion total. ITM’s shareholders will receive their shares as Nasdaq-listed American Depositary Receipts once escrow periods, running up to 15 months, expire.
On top of that, Telix has agreed to pay up to $700 million more if ITM’s lead drug candidate hits future regulatory and sales targets: as much as $250 million tied to three separate FDA approvals across different patient groups, on deadlines running from the end of 2027 through the end of 2031, plus up to $450 million if the drug’s 2030 global sales exceed $150 million. None of that money is owed unless those approvals and sales actually happen.
The deal is expected to close by the end of 2026, pending a Telix shareholder vote set for November and other regulatory sign-offs. Once it closes, existing Telix shareholders will hold roughly 76% of the combined company and ITM’s shareholders about 24%.
What the Release Leaves Out
ITM’s most advanced drug candidate is ITM-11 (177Lu-edotreotide), designed to treat gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, a group of rare, typically slow-growing cancers of the gut and pancreas. The merger announcement describes ITM-11 as having “successfully completed Phase 3 development,” and frames it as a near-term path into a validated commercial market. That is technically accurate but leaves out a material fact: on August 7, 2026, roughly six weeks before this merger was announced, the FDA issued a Complete Response Letter declining to approve ITM-11’s new drug application in its current form. The agency’s letter cited chemistry, manufacturing and controls issues and concerns about a third-party commercial facility, not the drug’s clinical data or safety profile, and ITM has said it intends to resubmit.
The only reference to this in the entire merger release is a single phrase buried in the boilerplate legal disclaimers, “the planned NDA resubmission for ITM-11,” with no explanation of what that refers to or why a resubmission is needed. ITM-11’s pivotal Phase 3 trial, called COMPETE, did report a meaningful progression-free survival advantage over the comparator drug everolimus. That data package has not yet cleared the FDA’s separate manufacturing bar, and readers weighing this deal should know both halves of that picture.
Not an Empty Field
If ITM-11 does eventually reach the U.S. market, it would compete against Lutathera, a chemically similar 177Lu-based drug Novartis has sold since 2018 for the same GEP-NET patient population. Radiopharmaceuticals have also drawn a wave of acquisitions industry-wide: Eli Lilly paid $1.4 billion for Point Biopharma in 2023, and Bristol Myers Squibb paid $4.1 billion for RayzeBio the same year, both to acquire radioligand pipelines. Telix’s headline price for ITM lands in a similar range to those deals, but the structure differs: Telix is buying the isotope manufacturer that supplies the whole field, not a single clinical-stage drug developer.
What Comes Next
Telix expects the combined company to generate more than $1.3 billion in pro forma 2026 revenue, according to unaudited management estimates, with a positive contribution to earnings before interest, tax, depreciation and amortization starting in 2027, a projection that depends on realizing cost synergies the companies have not yet itemized. The release does not disclose who currently owns ITM or what price the deal represents relative to ITM’s 2025 revenue, details investors may want ahead of the shareholder vote. This article covers a proposed corporate transaction and is not investment or medical advice.
Sources
Telix Pharmaceuticals Limited: Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse, PRNewswire, September 20, 2026. Primary source release.
ITM Isotope Technologies Munich SE: ITM Receives Complete Response Letter for 177Lu-edotreotide (ITM-11), August 10, 2026, cited for the FDA’s Complete Response Letter, which the merger release did not address in its body text.
European Society for Medical Oncology: FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETs, cited for Lutathera’s existing FDA approval in the same GEP-NET population that ITM-11 is targeting.
Reuters (via The Gazette): Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push, cited for comparable radiopharmaceutical M&A pricing.
GeneOnline: Eli Lilly Expands Oncology Portfolio with $1.4 Billion Acquisition of POINT Biopharma, cited for comparable radiopharmaceutical M&A pricing.
Pharma Manufacturing: ITM Opens World’s Largest Lutetium-177 Production Site, cited for independent verification of ITM’s isotope-production claims, which the merger release did not source.
Editorial Disclosure
This article is based on a press release issued jointly by Telix Pharmaceuticals Limited and ITM Isotope Technologies Munich SE on September 20, 2026, announcing Telix’s agreement to acquire ITM. Securities discussed: Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX). ITM Isotope Technologies Munich SE is a private company and is not currently listed on any public exchange. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Telix Pharmaceuticals, ITM, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. This article also draws on ITM’s own August 2026 disclosure of an FDA Complete Response Letter for ITM-11, independent reporting on comparable radiopharmaceutical acquisitions, and independent trade-press verification of ITM’s isotope-production claims, none of which appeared in the merger announcement itself, cited above. Statements regarding the timing and completion of the proposed transaction, projected pro forma revenue and EBITDA, future regulatory approvals and milestone payments for ITM-11, and anticipated cost synergies are forward-looking statements. They involve substantial risks and uncertainties, including whether Telix shareholders approve the transaction, whether required regulatory approvals are obtained, and whether ITM’s planned NDA resubmission for ITM-11 is ultimately successful; actual results may differ materially. Clinical-stage and commercial-stage biotechnology and radiopharmaceutical investments carry a high degree of financial risk. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. This content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.
For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.
